Overview
Kiniksa Q3 2025 ARCALYST revenue grows 61% yr/yr to $180.9 mln
Company raises 2025 ARCALYST revenue guidance to $670-$675 mln
KPL-387 granted Orphan Drug Designation for pericarditis treatment
Outlook
Kiniksa raises 2025 ARCALYST revenue guidance to $670 mln - $675 mln
Company expects to remain cash flow positive annually
Data from KPL-387 Phase 2/3 trial expected in H2 2026
Result Drivers
ARCALYST ADOPTION - Increased adoption of ARCALYST for recurrent pericarditis drove significant revenue growth
REVENUE GUIDANCE RAISED - Kiniksa raised 2025 ARCALYST revenue guidance due to strong performance
ORPHAN DRUG DESIGNATION - KPL-387 granted Orphan Drug Designation for pericarditis treatment
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Product Revenue | $180.85 mln | ||
Q3 EPS | $0.25 | ||
Q3 Net Income | $18.43 mln | ||
Q3 Operating Expenses | $156.83 mln | ||
Q3 Pretax Profit | $27.15 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International PLC is $47.50, about 14.5% above its October 27 closing price of $40.60
The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 29 three months ago
Press Release: ID:nGNX4GcZj6
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments